Vanda PharmaceuticalsVNDA +0.47%75 Days Payable is 135.94 as of Mar. 2026, which is 23% above its 10-year median of 110.20. GuruFocus rates VNDA with a GF Score™ of 75/100 and a GF Value™ of $5.48 (Fairly Valued). The stock has 4 warning signs investors should review. Among 705 Biotechnology companies, Vanda Pharmaceuticals ranks better than 52.06% on this metric.
Vanda Pharmaceuticals Days Payable Historical Data
* Premium members only.
The historical data trend for Vanda Pharmaceuticals's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vanda Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vanda Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vanda Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Vanda Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Vanda Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vanda Pharmaceuticals (VNDA) has a Days Payable of 135.94 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vanda Pharmaceuticals and its competitors. This is 23% above median its historical median of 110.20. Over the past decade, Vanda Pharmaceuticals' Days Payable has ranged from 14.06 to 244.65. According to the industry distribution chart, Vanda Pharmaceuticals ranks #338 out of 705 companies in the Biotechnology industry, placing it in the top 47.9%.
Is Vanda Pharmaceuticals' Days Payable too high?
Vanda Pharmaceuticals' current Days Payable of 135.94 is 23% above median its 10-year median of 110.20. Over the past 10 years, this metric has ranged from a low of 14.06 to a high of 244.65. The Biotechnology industry median Days Payable is 113.36. Vanda Pharmaceuticals' value of 135.94 is 19.9% above this industry median. Based on the distribution chart, Vanda Pharmaceuticals ranks #338 out of 705 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Vanda Pharmaceuticals has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vanda Pharmaceuticals' Days Payable compare to AVIR and OABI?
According to the Biotechnology industry distribution chart, Vanda Pharmaceuticals ranks #338 out of 705 companies for Days Payable. This puts Vanda Pharmaceuticals in the upper half of its industry. The industry median Days Payable is 113.36. Vanda Pharmaceuticals' value of 135.94 is 19.9% above this benchmark. Historically, Vanda Pharmaceuticals' own Days Payable has ranged from 14.06 to 244.65 over the past decade. While the company's 10-year median is 110.20 vs. the industry median of 113.36, Vanda Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.36, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vanda Pharmaceuticals's current Days Payable of 135.94 is 19.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Vanda Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vanda Pharmaceuticals's current Days Payable is 135.94, which is 23% above median its own 10-year median of 110.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vanda Pharmaceuticals (VNDA) is currently considered Fairly Valued. The stock's GF Value™ is $5.48, compared to a current price of $6.03 — trading 10% above its estimated fair value. The current Days Payable is 135.94, which is 23% above median its 10-year median of 110.20 and 19.9% above the Biotechnology industry median of 113.36. Vanda Pharmaceuticals' overall GF Score™ is 75/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Vanda Pharmaceuticals (VNDA), the current Days Payable is 135.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vanda Pharmaceuticals (VNDA) Overvalued in 2026?
Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be overvalued.
The current stock price of $6.03 is trading 10% above its estimated GF Value™ of $5.48.
GuruFocus considers Vanda Pharmaceuticals to be Fairly Valued.
Key valuation signals for VNDA:
Days Payable: 135.94 (23% above median its 10-year median of 110.20)
GF Value™: $5.48 vs. price of $6.03 (10% above fair value)
Industry Position: 19.9% above the Biotechnology median (#338 of 705)
No single metric tells the full story. See the VNDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
75GF Score
Get the complete analysis for VNDA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VNDA has been successfully added to your 
